News | Heart Failure | March 28, 2022

HeartPoint Global's Implant System Proves Safety and Efficacy

This new milestone follows the company’s successful exploration of the HeartPoint Global Implant System in the arterial branches

HeartPoint Global, a leading medical device company dedicated to providing high-quality, minimally invasive cardiac care globally, announced another major milestone in the ongoing pre-clinical trials of the HeartPoint Global Implant System (HPGS), a first-of-its-kind patented, adjustable system which focuses on treating devastating left heart diseases, congestive heart failure, and structural pulmonary hypertension.

Getty Images


March 28, 2022 — HeartPoint Global, a leading medical device company dedicated to providing high-quality, minimally invasive cardiac care globally, announced another major milestone in the ongoing pre-clinical trials of the HeartPoint Global Implant System (HPGS), a first-of-its-kind patented, adjustable system which focuses on treating devastating left heart diseases, congestive heart failure, and structural pulmonary hypertension.

Landmark findings from a successful pre-clinical study recently completed in conjunction with Hadassah University Hospital at Lahav CRO, Israel’s largest contract research organization pre-clinical center specializing in large animal studies, included: 

·        Long term data proving that the HeartPoint Implant System (HPIS) caused a significant restriction to blood flow and effectively maintained the reduced pressure gradient over the five-month period of the study.

·         Data proving that even a major reduction in the pressure gradient did not result in thrombus, blockages, or negative biological responses. The results of this pre-clinical trial for the HeartPoint Global Implant System go against the mainstream theory that reduction of the diameter in highly pressurized vessels to the extent reduced in the study would most likely result in thrombus formation and/or implant occlusion.

·        The observation of positive structural alterations to the hearts in echo and gross pathology. Maintaining the resulting gradient from the HeartPoint Global Implant System demonstrated septum shift and right ventricle enlargement. This significant pronounced structural change to the heart suggests the ability to target a lower gradient boosting safety margins for human patients.

Further exploring the unique placements of the Heartpoint Global Implant System, this newest trial also proved that the HPGS could navigate the most torturous curves in vivo, deliver successful deployments, and accomplish stent recapture. Previous successful pre-clinical tests of the implant system studied the direct placement of the device in the main pulmonary artery and the arterial branches and allowed for the adjustment of blood flow in the heart lung system. The interventions were performed by Dr. David Planer, Head of Interventional Cardiology, and Dr. Gabby Elbaz-Greener, both of Hadassah Medical Center.

“Providing a treatment for cardiovascular diseases that is both minimally invasive, adjustable at any time, and affordable is of paramount importance,” said Seth Bogner, Chairman and CEO of HeartPoint Global. “Throughout the pre-clinical testing process, our groundbreaking technology has demonstrated the ability to significantly improve the structure of the heart and the function of the heart-lung system. We are encouraged by the positive results we have seen thus far and look forward to starting our clinical trials imminently.”

This pre-clinical trial follows HeartPoint Global’s announcement of the successful exploration of the HPGS in the arterial branches that was announced in January. The innovative placement resulted in a septum shift and a reaction in the tricuspid valve, indicating that left heart diseases can also be treated with a Heartpoint Global intervention in the arterial branches. HeartPoint Global is scheduled to perform clinical trials in Europe shortly.

According to the World Health Organization, cardiovascular diseases are the world’s leading cause of death, with more than three-quarters of these deaths occurring in low- and middle-income countries. HeartPoint Global is addressing this issue by developing the first and only minimally invasive adjustable heart-lung system that brings affordability, accessibility, and the potential to save millions of lives in the developed and developing world.

In the U.S. and Western Europe, Heartpoint Global treats left heart issues, the largest subset of congestive heart failure, and the leading cause of mortality in the world. However, most of the market for HeartPoint Global’s flagship product, the HeartPoint Global Implant System, is in the developing world. Heartpoint Global will not only treat left heart issues but also children and adults who have developed various conditions due to undetected congenital defects. Heartpoint Global aims to serve both markets, the developed world through conventional well-established distribution systems, and the developing world through our Train the Doctor (TDP) program.

For more information: https://www.heartpointglobal.com/

Related Content

News | Heart Failure

June 29, 2022 — A spiral wave of electrical activity in the heart can cause catastrophic consequences. One spiral wave ...

Home June 29, 2022
Home
News | Heart Failure

June 29, 2022 — Adult survivors of cancer have a higher risk of heart failure and other cardiovascular diseases (CVD) ...

Home June 29, 2022
Home
News | Heart Failure

June 29, 2022 — While lower vertebrates can repair their adult hearts after a heart attack, mammals — including humans — ...

Home June 29, 2022
Home
News | Heart Failure

June 27, 2022 — Results from one of the largest global studies of atrial fibrillation (AFib) procedures show that the ...

Home June 28, 2022
Home
News | Heart Failure

June 22, 2022 — Recommendations on how to use gene testing to prevent sudden cardiac death in athletes and enable safe ...

Home June 22, 2022
Home
News | Heart Failure

June 22, 2022— Researchers at The Ohio State University Wexner Medical Center and College of Medicine have developed a ...

Home June 22, 2022
Home
News | Heart Failure

June 20, 2022— Marc Chatzky may not feel like a cardiac pioneer, but he is, at least in South Florida. The Deerfield ...

Home June 20, 2022
Home
News | Heart Failure

June 10, 2022 — Individuals with diabetes display a substantially increased risk of disease in left-sided heart valves ...

Home June 10, 2022
Home
News | Heart Failure

June 9, 2022 — Memorial Regional Hospital recently entered elite company, becoming just the fourth hospital in the ...

Home June 09, 2022
Home
News | Heart Failure

June 3, 3033 — Esperion announced findings from a real-world analysis of more than 400,000 patients at high-risk for ...

Home June 03, 2022
Home
Subscribe Now